logo

For the Inventor, By the Inventor

Fremont, CA, United States of America

Abgenix, Inc.


USPTO Granted Patents = 32

% Expired Patents = 18.8



Forward Citations = 6,796

Loading Chart...
Loading Chart...

52 inventors (with patents filed for the assignee):

goldMedal Aya Jakobovits (14 out of 191 patents)

silverMedal Raju S Kucherlapati (8 out of 18 patents)

bronzeMedal Jose Corvalan (7 out of 34 patents)

4.  Daniel J Capon (6 out of 32 patents)

5.  Larry L Green (6 out of 71 patents)

6.  Daniel G Brenner (6 out of 7 patents)

7.  Sue Klapholz (5 out of 11 patents)

8.  Xiao-Chi Jia (4 out of 57 patents)

9.  Vahe Bedian (4 out of 29 patents)

10.  Krisztina M Zsebo (4 out of 30 patents)

11.  Ronald P Gladue (3 out of 15 patents)

12.  Xiao Feng (3 out of 22 patents)

13.  C Geoffrey Davis (3 out of 15 patents)

14.  Menashe Bar-Eli (3 out of 4 patents)

15.  Michael Gallo (2 out of 20 patents)


Core Competencies:
Monoclonal Antibody
Cancer Treatment
Immune Response
CD40 Antibodies
Interleukin-5
Transgenic Animals
Xenogeneic Antibodies
MUC18 Antigen
Site-Specific Recombination
Cell Fusion
Genomic DNA Deletions

32 patents:

1. 8236530 - Method for preparing monoclonal antibody (2012-08-07),
2. 7563442 - Antibodies to CD40 and methods of treating cancer and enhancing immune responses (2009-07-21),
3. 7422742 - Methods for using human monoclonal antibodies to interleukin-5 (2008-09-09),
4. 7338660 - Methods of treating cancer and enhancing immune responses with antibodies that bind CD40 (2008-03-04),
5. 7326414 - Antibodies to M-CSF (2008-02-05),
6. 7288251 - Antibodies to CD40 (2007-10-30),
7. 7202343 - Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof (2007-04-10),
8. 7145056 - Production of antibodies using cre-mediated site-specific recombination (2006-12-05),
9. 7141653 - Human monoclonal antibodies to interleukin-5 (2006-11-28),
10. 7109003 - Methods for expressing and recovering human monoclonal antibodies to CTLA-4 (2006-09-19),
11. 7090844 - Use of antibodies against the MUC18 antigen (2006-08-15),
12. 7078492 - Human antipneumococcal antibodies from non-human animals (2006-07-18),
13. 7067131 - Methods for using anti-MUC18 antibodies (2006-06-27),
14. 7064244 - [object Object] (2006-06-20),
15. 7049426 - Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions (2006-05-23),
Company Overview
Abgenix, Inc. is a biotechnology company based in Fremont, California, specializing in the development of therapeutic antibodies for the treatment of various diseases. The company focuses on innovative approaches to antibody engineering, leveraging its proprietary technologies to create targeted therapies that address unmet medical needs. Abgenix is committed to advancing the field of immunotherapy, contributing to the development of treatments that enhance patient outcomes in oncology and other therapeutic areas.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Abgenix, Inc. USPTO Patent Assignee Logo
32 Patents

#69 in Fremont, CA

#2,532 in California

#10,593 in US

#20,660 in the World

Fremont, CA (US)
Fremont, CA, United States of America

Abgenix, Inc.

Forward Citations = 6,796

52 inventors:

goldMedal Aya Jakobovits (14 out of 191 patents)

silverMedal Raju S Kucherlapati (8 out of 18 patents)

bronzeMedal Jose Corvalan (7 out of 34 patents)

4.  Daniel J Capon (6 out of 32 patents)

5.  Larry L Green (6 out of 71 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Abgenix, Inc.. Retrieved from https://idiyas.com/company/abgenix

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…